Michael Reardon: TMVR (Medtronic Apollo Trial)

Randolph Martin, MD, and Michael Reardon, MD, talk about transcatheter mitral valve replacement. Dr. Reardon shares key learnings from the Medtronic APOLLO trial thus far. The study has shown that transcatheter mitral valve replacement is much more complex that with the aortic valve requiring more complex interplay between imaging and catheter techniques. A dramatic finding is that TMVR can eliminate regurgitation entirely.
Dr. Reardon explains the main issue so far is patient selection and attention to the LVOT [Left Ventricular Outflow Tract]. He believes that if TMVR can be done safely and is reproducible, then it could be a competitive therapy. There are some exciting therapies that Dr. Reardon believes will come along in the next few years, but he stresses that the role of surgeons continues to be of central importance.
Michael Reardon, MD
Professor of Cardiothoracic Surgery
Allison Family Distinguished Chair of Cardiovascular Research Methodist DeBakey Heart & Vascular Center
Randolph P. Martin, MD
Clinical Professor, Department of Cardiovascular Surgery
Icahn School of Medicine at Mount Sinai
About the AATS Mitral Conclave:
David H. Adams, MD, and Anelechi C. Anyanwu, MD, serve as the Program Directors of the AATS Mitral Conclave - a meeting that Dr. Adams created with the American Association for Thoracic Surgery in 2011. The biennial meeting brings the world’s leading experts together to examine all aspects of mitral valve disease, associated conditions, and treatment. The meeting featured more than 350 presentations, 40 focused breakout or lunch sessions, combined with four main plenary sessions - with over 900 attendees from 52 countries.